ITC Requests Public Input on Remedies for Viking Therapeutics Section 337 Investigation
The International Trade Commission is seeking public input on remedies for its Section 337 investigation of Viking Therapeutics' drug VK2809, after determining to review the administrative law judge's final initial determination finding a violation of Section 337, the ITC said…
Sign up for a free preview to unlock the rest of this article
Communications Daily is required reading for senior executives at top telecom corporations, law firms, lobbying organizations, associations and government agencies (including the FCC). Join them today!
in a notice to be published Feb. 19. The ITC initially began the investigation in February 2023 based on allegations that five companies misappropriated Viking’s trade secrets related to the development of the drug (see 2302080004). The ALJ's initial determination granted the complainant's motion regarding the misappropriation of the asserted trade secrets and recommended a limited exclusion order should the ITC find a violation. The ITC is requesting written submissions by “close of business” on Feb. 28.